NanoVibronix Inc

+0.35 (+136.36%)
4:11:12 PM EDT: $0.60 -0.01 (-1.68%)

Nanovibronix Provides Business Update In Letter To Shareholders

Published: 11/15/2022 13:56 GMT
NanoVibronix Inc (NAOV) - Nanovibronix Provides Business Update in Letter to Shareholders.
Nanovibronix Inc - Approval of Painshield Plus by U.S. Food and Drug Administration (fda) Has Been Slower Than We Had Hoped.
Nanovibronix Inc - Following Submission of a Special 510k Application on Painshield Plus, FDA Asked for Clarifications.
Nanovibronix Inc - FDA Requested That We Discontinue Any New Marketing of Our Painshield Plus Products Until We Receive Formal Approval.
Nanovibronix Inc - Engaged With Two Engineering Firms to Assist With Preparation of Additional Test Data That Was Requested by FDA for Painshield Plus.
Nanovibronix Inc - Continue to Believe That Upon Approval, Painshield Plus Will Be Back on Track and Increase Our Revenue From Certain Channels.
Nanovibronix Inc - Anticipate Two Additional Studies to Be Initiated in Early 2023 for Uroshield.